( 母液浓度为 40 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们客服联系。| 中文名称: | NSC781406 一键复制产品信息 | ||||
|---|---|---|---|---|---|
| 英文名称: | NSC781406 | ||||
| 别名: | NSC781406 2,4-Difluoro-N-[2-methoxy-5-[4-[3-(4-methylsulfonylpiperazin-1-yl)prop-1-ynyl]quinolin-6-yl]pyridin-3-yl]benzenesulfonamide | ||||
| CAS No: | 1676893-24-5 | 分子式: | C29H27F2N5O5S2 | 分子量: | 627.68 |
| CAS No: | 1676893-24-5 | ||||
| 分子式: | C29H27F2N5O5S2 | ||||
| 分子量: | 627.68 | ||||
基本信息
|
产品编号: |
N11404 |
||||
|
产品名称: |
NSC781406 |
||||
|
CAS: |
1676893-24-5 |
储存条件 |
粉末 |
-20℃ |
四年 |
|
|
|
||||
|
分子式: |
溶于液体 |
-80℃ |
6个月 |
||
|
分子量: |
627.68 |
-20℃ |
1个月 |
||
|
化学名: |
2,4-Difluoro-N-[2-methoxy-5-[4-[3-(4-methylsulfonylpiperazin-1-yl)prop-1-ynyl]quinolin-6-yl]pyridin-3-yl]benzenesulfonamide |
||||
|
Solubility (25°C): |
|||||
|
体外:
|
DMSO |
|
|||
|
Ethanol |
|
||||
|
Water |
|
||||
|
体内(现配现用): |
|
||||
|
<1mg/ml表示微溶或不溶。 |
|||||
|
普西唐提供的所有化合物浓度为内部测试所得,实际溶液度可能与公布值有所偏差,属于正常的批间细微差异现象。 |
|||||
|
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;⼀旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |
|||||
制备储备液
|
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
|
1mM |
1.5932mL |
7.9658mL |
15.9317mL |
|
5mM |
0.3186mL |
1.5932mL |
3.1863mL |
|
10mM |
0.1593mL |
0.7966mL |
1.5932mL |
生物活性
|
产品描述 |
一种高效的PI3K和mTOR抑制剂,对PI3Kα的IC50值为2nM。 |
|
靶点 |
PI3K;mTOR |
|
体外研究 |
NSC781406 demonstrates potent PI3K inhibition (PI3KαIC50=2.0nM) that translates into BEL-7404 cells proliferation inhibition (IC50=20nM).NSC781406 displays reasonable liver microsome stability.NSC781406 demonstrates cytotoxic activities against leukemia,non-small cell,lung cancer,colon cancer,central nervous system cancer,melanoma,ovarian cancer,renal cancer,prostate cancer,and breast cancer.It is potent against 60 cancer cell lines with a mean GI50 value of 65nM,and with a GI50 value less than 10nM against four cancer cell lines. |
|
体内研究 |
In the xenograft models, treatment with 30mg/kg of NSC781406 results in statistically significant antitumor activity,with a mean reduction in relative tumor volume ratio of 52%.Sorafenib displays an inhibition ratio of 44% at 50mg/kg.NSC781406 is well tolerated at 30mg/kg,with no observed mortality or significant reduction of body weight. |
推荐实验方法(仅供参考)
|
激酶实验: |
|
IC50 values for inhibition of the PI3K is measured.PI-103 is used as the reference compound.The compounds (NSC781406) are tested in duplicate for 10 concentrations,100nM or 500nM as the top concentration.All reagents are diluted in kinase buffer.Three-fold,ten-point serial compound (NSC781406) dilutions are performed in kinase buffer. |
|
细胞实验: |
|
|
Cytotoxic effects are tested in the human lung adenocarcinoma cells A549,human colon cancer cells HCT-116,human breast cancer cells MDA-MB-231 and human hepatocellular carcinoma cells BEL-7404.These four tumor cells are diluted to a density of 40,000–50,000 cells/mL in logarithmic phase.After the cells are treated with compounds (NSC781406) for 72h,MTT solution (5mg/mL,20μL) is added another 4h at 37℃.IC50 values are determined by a nonlinear regression analysis. |
|
|
动物实验: |
|
|
Mice:NSC781406 is orally administered once a day 30mg/kg for 14 consecutive days or with sorafenib at 50mg/kg.The relative tumor volume to vehicle-treated control mice is monitored. |
|
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液,使用的计算公式为:
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为:C1V1 = C2V2 ( 输入 输出 )
母液,添加 300 μLPEG300
混匀澄清,再加 50μLTween80, 混匀澄清,再加 600μLSaline/PBS/ddH2O
混匀澄清方案所需的各种助溶剂如: DMSO , PEG300 / PEG400 , Tween 80 , SBE-β-CD , 玉米油 等, 均可点击跳转或在网站搜索购买。
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
.png)
